Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) Products under Development by Stage of Development | 7 | 1 |
| Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) Products under Development by Therapy Area | 8 | 1 |
| Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) Products under Development by Indication | 9 | 1 |
| Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) Products under Development by Companies | 12 | 2 |
| Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) Products under Development by Universities/Institutes | 14 | 2 |
| Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) Therapeutics Assessment | 16 | 6 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 1 |
| Assessment by Route of Administration | 18 | 2 |
| Assessment by Molecule Type | 20 | 2 |
| Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) Companies Involved in Therapeutics Development | 22 | 5 |
| Atlantic Healthcare Plc | 22 | 1 |
| China Medical System Holdings Limited | 23 | 1 |
| DiNonA Inc. | 24 | 1 |
| MingSight Pharmaceuticals | 25 | 1 |
| RXi Pharmaceuticals Corporation | 26 | 1 |
| Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) Drug Profiles | 27 | 8 |
| alicaforsen sodium Drug Profile | 27 | 2 |
| CMS-024 Drug Profile | 29 | 1 |
| DNP-003 Drug Profile | 30 | 1 |
| melittin Drug Profile | 31 | 1 |
| MS-553 Drug Profile | 32 | 1 |
| Peptides to Inhibit Fibrinogen and ICAM-1 for Oncology, Immunology, Cardiovascular, Musculoskeletal and Hematological Disorders Drug Profile | 33 | 1 |
| RNAi Oligonucleotide to Inhibit ICAM-1 for Retinal Diseases and Cancer Drug Profile | 34 | 1 |
| Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) Dormant Projects | 35 | 1 |
| Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) Discontinued Products | 36 | 1 |
| Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) Featured News &Press Releases | 37 | 5 |
| Feb 11, 2016: Atlantic Healthcare starts pivotal Phase 3 trial of Alicaforsen to treat Inflammatory Bowel Disease Pouchitis | 37 | 1 |
| Jan 28, 2011: CMS Expects To Launch CMS024 For Treatment Of Primary Liver Carcinoma Three Years Ahead Of Plan In 2013 | 37 | 2 |
| Jul 08, 2008: FDA Grants Orphan Drug Designation For Alicaforsen | 39 | 1 |
| Dec 02, 2004: Isis Pharmaceuticals Announces Phase 3 Clinical Trials Results Of Alicaforsen With Crohn's Disease | 39 | 1 |
| Dec 02, 2004: Isis Pharmaceuticals Inc. Announces Phase II clinical Trials Of Alicaforsen For Ulcerative Colitis | 40 | 1 |
| Apr 08, 2003: Isis Pharmaceuticals Initiates Additional Phase II Clinical Trial Of Alicaforsen, ISIS 2302, In Patients With Ulcerative Colitis | 40 | 2 |
| Appendix | 42 | 2 |
| Methodology | 42 | 1 |
| Coverage | 42 | 1 |
| Secondary Research | 42 | 1 |
| Primary Research | 42 | 1 |
| Expert Panel Validation | 42 | 1 |
| Contact Us | 42 | 1 |
| Disclaimer | 43 | 1 |